Vir Biotechnology (VIR) Cash from Operations (2018 - 2026)

Vir Biotechnology (VIR) has 9 years of Cash from Operations data on file, last reported at 132386000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 69.47% year-over-year to 132386000.0; the trailing twelve-month figure through Mar 2026 stood at 446051000.0 (down 7.46% YoY), and the FY2025 full-year result was 391781000.0, up 12.23% from the prior year.
• Cash from Operations declined to 132386000.0 in Q1 2026, from 25876000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 960136000.0 in Q2 2022 to a low of 389247000.0 in Q2 2023.
• A 5-year average of 5061823.53 and a median of 107927000.0 in 2023 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations jumped 714.43% in 2022 and slumped 407.26% in 2023, its largest moves.
• Tracing VIR's Cash from Operations over 5 years: stood at 35126000.0 in 2022, then tumbled by 407.26% to 107927000.0 in 2023, then climbed by 18.8% to 87635000.0 in 2024, then jumped by 70.47% to 25876000.0 in 2025, then plunged by 411.62% to 132386000.0 in 2026.
• Business Quant data shows VIR's Cash from Operations at 132386000.0 in Q1 2026, 25876000.0 in Q4 2025, and 167570000.0 in Q3 2025.